Financhill
Back

TC BioPharm (Holdings) PLC Quote, Financials, Valuation and Earnings

Sell
14

TCBP
TC BioPharm (Holdings) PLC

Last Price:
1.13
Seasonality Move:
-50.26%

7 Day Trial

ALL ACCESS PASS

$ 7

TC BioPharm (Holdings) PLC Price Quote

$1.13
-0.01 (-0.88%)
(Updated: May 17, 2024 at 6:55 PM ET)

TC BioPharm (Holdings) PLC Key Stats

Sell
14
TC BioPharm (Holdings) PLC (TCBP) is a Sell

Day range:
$1.10 - $1.16
52-week range:
$0.85 - $20.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.08
P/B ratio:
1.06%

Volume:
252.2K
Avg. volume:
1.9M
1-year change:
-92.4%
Market cap:
$3.6M
Revenue:
$0
EPS:
$-5.06

How Much Does TC BioPharm (Holdings) PLC Make?

Data Unavailable

Is TC BioPharm (Holdings) PLC Growing As A Company?

Data Unavailable

TC BioPharm (Holdings) PLC Stock Price Performance

What Is TC BioPharm (Holdings) PLC 52-Week High & Low?

TC BioPharm (Holdings) PLC Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy TC BioPharm (Holdings) PLC?

Is TC BioPharm (Holdings) PLC Cash Flow Positive?

  • What Is TCBP Cash Flow From Operations?
    Cash flow from operations (TTM) is -$13.2M
  • What Is TC BioPharm (Holdings) PLC’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $10.6M
  • What Is TC BioPharm (Holdings) PLC’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$261.4K

TC BioPharm (Holdings) PLC Return On Invested Capital

Data Unavailable

TC BioPharm (Holdings) PLC Earnings Date & Stock Price

TC BioPharm (Holdings) PLC Competitors

TC BioPharm (Holdings) PLC Dividend Yield

Data Unavailable

TC BioPharm (Holdings) PLC Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 140.00
Upside from Last Price: 12180.7%

Major Shareholders

  • How many TCBP shares are owned by institutional investors?
    131.1K TCBP shares are owned by institutional investors
  • How many TCBP shares are owned by insiders?
    0 TCBP shares are owned by insiders